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The role of drug susceptibility testing in M/XDR-TB. Too little
and too late – Are we doing the right things?Severely drug resistant Mycobacterium tuberculosis (MTB) is
increasingly recognized as an important public health con-
cern and is causing significant problems and costs for many
national TB control programs. In some settings of the former
Soviet Union, the prevalence of multidrug resistant (MDR)-TB
is close to 50% and around one third of all newly detected TB
patients are infected with MDR-TB [1]. Without any doubt, pa-
tients with such strains transmit drug resistant TB and the
spread of certain MDR-TB clones constitutes an important
part of the problem at least in high MDR-TB burden countries
[2]. Fortunately, we do know what kind of actions are needed
to counteract this worrying situation; these are primarily the
timely modification of TB treatment to effective combinations
of drugs rendering the patient non-infectious, and increased
infection control measures in settings where transmission is
detected or suspected. So why is this not generally done?
In my opinion, one important reason is clear: we fail to de-
tect the MDR-TB cases, at least to detect them early enough to
be able to take the necessary actions in a timely way. Accord-
ing to an estimate from the World Health Organization (WHO)
[3], in 2011 less than 4% of new laboratory-confirmed cases
and 6% of previously treated cases globally were tested for
the susceptibility to the two MDR-defining drugs–rifampicin
and isoniazid. Particularly low figures were seen in Africa
and South-East Asia. In the European Region of WHO where
the highest incidence of MDR-TB is found, the situation is
somewhat better, but still far from good; 56% of new and
27% of previously treated cases were tested. Among non-
European high MDR-TB burden countries, the testing for
MDR-TB in new cases was highest in China (2.6%). It is thus
obvious that a strong majority of the global MDR-TB patients
is not detected and will thus get inappropriate therapy and
continue to transmit resistant TB. They are also at risk for
developing even more resistant forms of TB, since exposure
to suboptimal drug combinations will favor both additional
development/selection of drug resistance and transmission
of increasingly resistant MTB strains in the community.
Not even one out of four laboratory-confirmed MDR-TB
cases in 2011 had DST results for the XDR-TB defining com-
pounds: fluoroquinolones and second-line injectable drugs
[4]. Without any doubt, we have a major quantitative problem
in the detection of M/XDR-cases. How about the quality of
testing?It will of course vary, and it is not possible to have the full
picture. But I do believe things are moving in the right direc-
tion. The global network of WHO Supranational Reference
Laboratories for TB now offers external quality assurance by
panel testing not only for first-line drugs, but also for the
XDR-defining second-line agents. It is important to strength-
en this activity in a sustainable way and to find a long-term
financial solution to maintain it. It is, however, not enough
that the national reference laboratories are quality assured.
Every national TB control program should, together with its
NRL, develop and implement a national quality management
system for all laboratories performing DST of MTB in their
country.
With today’s knowledge, available diagnostic tools and epi-
demiological situation regarding M/XDR-TB, it cannot be con-
sidered acceptable to have to wait for 8–10 weeks to know if a
clinical isolate is susceptible or not. Thus, the generally used
algorithm of isolation on solid media followed by subsequent
DST on solid media must be seen as obsolete. Unfortunately,
globally this is still likely the most commonly used way to de-
tect drug resistance in MTB. Today, we have automated cul-
turing systems [4] that significantly shorten the turnaround
time, but I believe the future is molecular PCR-based assays.
Besides a number of locally developed non-commercial such
assays, there are mainly two commercial alternatives; the
GeneXpert from Cepheid and a number of line probe assays
(LPA) from Hain Life Science. The Xpert system [5] is the most
rapid technique, and it is developed to be easy to use. It offers
the simultaneous detection of MTB and resistance to rifampi-
cin in, for example, a smear-positive sputum sample. Often,
rifampicin resistance is seen as a proxy for MDR-TB, but this
praxis is not undisputed, and it has been reported that rifam-
picin resistance is not a valid MDR marker everywhere [6,7].
The LPA [8] is more informative since it investigates resis-
tance to both rifampicin and isoniazid. It is, however, some-
what more time-consuming and more laborious to perform.
Both these assays have demonstrated excellent specificity
(for both drugs) and sensitivity (rifampicin). The sensitivity
to detect resistance to isoniazid is somewhat lower, since
the underlying molecular resistance mechanisms in this case
are more complicated than for rifampicin.
However, all data on specificity and sensitivity must be ta-
ken with some caution, since the prevalence of drug resis-
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tings [9], so will the characteristics of molecular tests. An
exception to the high sensitivity to detect resistance is re-
ported in patients with so-called hetero-resistant TB. This is
the case when a patient harbors both susceptible and resis-
tant bacteria, which can happen during the phase of develop-
ing resistance and when an individual is infected with one
resistant and susceptible strain of MTB. In these cases, cul-
ture-based DST has been shown to be more sensitive to detect
a minority of both rifampicin [10] and isoniazid [11] resistant
bacterial cells. There is also an LPA for rapid detection of XDR-
TB, but before this test could be generally recommended, it
needs to be improved concerning the sensitivity to identify
resistance to the second-line injectable drugs.
Molecular assays offer early warning systems to MTB
resistance. This is crucially important both from a public
health and clinical perspective since it makes early optimiza-
tion of therapy possible to tender the individual patient non-
infectious and subsequently cured.
In my opinion we should, whenever possible, aim at know-
ing more than the possible resistance to rifampicin; if the bac-
teria is resistant, we need to combine the remaining drugs in
an effective way; if it susceptible, we risk fueling the develop-
ment of MDR if isoniazid and the other components of the
standard first-line therapy is jeopardized by (undetected)
resistance to some or all of them. Further development and
improvements of existing tests should be given priority, as
well as implementation of QMS for their use. Each country
should develop national diagnostic algorithms for how, if
and when rapid molecular assays should be combined with
phenotypic DST. This will aim at ensuring a correct and
timely diagnostic service in the fight against M/XDR-TB, but
will depend on the local epidemiological situation, as well
as what is financially possible, and the availability of cul-
ture/DST laboratories. PZA has a special role. It is an impor-
tant first-line drug, which has also been proven to be very
useful in the therapy of M/XDR-TB if the strain is susceptible.
Due to its importance for treatment and outcome, it was re-
cently suggested that MDR strains be classified as MDR-Zs
and MDR-Zr for PZA susceptible and resistant strains respec-
tively [12]. PZA has also been shown to have an important role
in combination with the new drug bedaquiline [13]. Consider-
ing this, two problems are of great concern: first, in contrast
to other first- and second-line TB drugs, there is no generally
accepted, affordable and applicable DST assay for PZA. In the
coming WHO-recommendations, only the commercial liquid
culturing system, MGIT (B&D) is recommended, and, sec-
ondly, no generally available system for EQA of PZA DST is
established. This leads to the fact that data on PZA suscepti-
bility, at least quality assured data, are almost totally lacking
from high incidence MDR-TB areas [14] where they would be
most needed. The important role of EQA for PZA was recently
illustrated in a study from Sweden [15]. In my opinion, we ur-
gently need both new tests and proficiency testing of them
developed and implemented. Molecular tests seem most
promising, but sequencing of the pncA gene, related to PZA
resistance, showed an unfortunate and unexpected wide dis-
tribution of resistant-related mutations throughout the gene
[16]. This will make development of molecular tests for PZA
more challenging than for most other TB-drugs.There are many challenges to meet, but increasing the cov-
erage of diagnostic DST to urgently ensure a correct and timely
diagnosis of M/XDR-TB should be a priority. Thus, the labora-
tory capacity to perform quality assured DST must be in-
creased, as well as new rapid diagnostic tests developed,
evaluated and implemented in the routine diagnostic algo-
rithms. We must shape up, and ensure the necessary financial
resources, facilities and appropriate staff to meet increasing
demands for timely, quality diagnostic support to identify
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